A prospective, open-label clinical trial, to evaluate the efficacy of intravitreal Aflibercept for the treatment of previously treated exudative age-related macular degeneration

Andrew Chang0 个研究点目标入组 70 人开始时间: 2012年6月21日最近更新: 2020年1月13日

试验速览

暂无简介。

•1. Ability to provide informed consent and complying with the study assessments who are the
•2. Age 50 years or older
•3. Choroidal neovascularization secondary to age-realted macular degeneration
•4. Best corrected vision between 6/6 to 6/60 on EDTRS chart
•5. Presence of subretinal fluid or cystic intraretinal oedema on optical coherence tomography after at least 4 anti-VEGF treatments within minimum of 6 months and maximum of 3 years before enrollment of the study
•6. Documentation of the presence of subretinal fluid or cystoid oedema less than 30 days since last treatment.

•1. Pregnancy or lactation
•2. Premenopausal women not using contraception
•3. Prior anti-VEGF injection in the study eye within 30 days of baseline
•4. Prior treatment with PDT (Visudyne) within 90 days of baseline and more than 6 prior PDT treatments
•5. Significant subretinal fibrosis or atrophy
•6. Prior treatment with triamcinolone in the study eye within 6 months of baseline
•7. Intraocular surgery in the study eye within 2 months of baseline
•8. Prior vitrectomy or other surgical intervention for age-realted macular degeneration in the study eye
•9. Current vitreous haemorrhage or inflammation in the study eye
•10. Uncontrolled glaucoma I the study eye. Intraocular pressure greater than 30mmHg on maximal medical therapy
•11. History of stroke, acute myocardial infarction and transient ischemic attack within 3 months of study enrollment
•12. Allergy to fluorescein and indocyanine green dye.

发起方

Andrew Chang